Patents/Inventors

Nathanael S. Gray

Boston, MAUS54 patents

48 Patents

US125706202026
Covalent Inhibitors of Creatine Kinase (CK) and Uses Thereof for Treating and Preventing Cancer
Dana-farber Cancer Institute, Inc.
0 cites
US125645912026
HCK as a Therapeutic Target in MYD88 Mutated Diseases
Dana-farber Cancer Institute, Inc.
0 cites
US125594572026
Sulfonamide Derivatives for Protein Degradation
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US125515632026
ERK5 Degraders as Therapeutics in Cancer and Inflammatory Diseases
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
USRE0507762026
Inhibitors of Cyclin-dependent Kinases
Dana-farber Cancer Institute, Inc.
0 cites
US125094552025
Imidazopyridine Derivatives and Aza-imidazopyridine Derivatives as Janus Kinase 2 Inhibitors and Uses Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US124973982025
Potent and Selective Covalent Inhibitors of Serine-arginine Protein Kinase (SRPK) 1 and SRPK2 and Uses Thereof
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US124912512025
Degraders of Cyclin-dependent Kinase 7 (CDK7) and Uses Thereof
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US124798472025
Pyrrolopyrimidine Inhibitors of Wild-type and Mutant Forms of LRRK2
VORONOI Inc.
0 cites
US124158162025
Benzothiazole Derivatives and 7-aza-benzothiazole Derivatives as Janus Kinase 2 Inhibitors and Uses Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US124101942025
Potent and Selective Azaindole Inhibitors of CDK8 and CDK19
Dana-farber Cancer Institute, Inc.
0 cites
US123981452025
Bicyclic Urea Kinase Inhibitors and Uses Thereof
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US123916712025
Allosteric EGFR Inhibitors and Methods of Use Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US123770802025
Allosteric EGFR Inhibitors and Methods of Use Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US123656642025
Small Molecule Inhibitors of SRC Tyrosine Kinase
Board Of Regents Of The University Of Texas System
0 cites
US123656772025
Degraders That Target Proteins via KEAP1
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US123298212025
Degradation of Bruton's Tyrosine Kinase (BTK) by Conjugation of BTK Inhibitors with E3 Ligase Ligand and Methods of Use
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US123310372025
Pyrimidines as Egfr-inhibitors and Methods of Treating Disorders
Dana-farber Cancer Institute, Inc.
0 cites
US123257252025
Cyclin-dependent Kinase Degraders and Methods of Use
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US123184522025
Degraders of WEE1 Kinase
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US122811262025
Inhibitors of Cyclin-dependent Kinase 7 and Uses Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US122757312025
Azaindole Inhibitors of Wild-type and Mutant Forms of LRRK2
VORONOI Inc.
0 cites
US122331282025
Degraders That Target ALK and Therapeutic Uses Thereof
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US122090762025
Imidazolyl Kinase Inhibitors and Uses Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US121877012025
Taire Family Kinase Inhibitors and Uses Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US121686632024
0 cites
US121616492024
Inhibitors of EGFR and Methods of Use Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US121577382024
Macrocyclic Inhibitors of ALK, TRKA, TRKB, and ROS1
Dana-farber Cancer Institute, Inc.
0 cites
US121577412024
Macrocyclic Inhibitors of DYRK1A
Voronoi Inc.
0 cites
US121215212024
Uses of Salt-inducible Kinase (SIK) Inhibitors for Treating Osteoporosis
Dana-farber Cancer Institute, Inc.
0 cites
US121230192024
Uses of Kinase Inhibitors for Inducing and Maintaining Pluripotency
Dana-farber Cancer Institute, Inc.
0 cites
US120981542024
Inhibitors of Cyclin-dependent Kinases
Dana-farber Cancer Institute, Inc.
0 cites
USRE0500302024
Methods to Treat Lymphoplasmacytic Lymphoma
Dana-farber Cancer Institute, Inc.
0 cites
US119458162024
Inhibitors of EGFR And/or HER2 and Methods of Use
Dana-farber Cancer Institute, Inc.
0 cites
US119326252024
Inhibitors of Cyclin-dependent Kinase 12 (CDK12) and Uses Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US119326462024
Small Molecule Myristate Inhibitors of Bcr-abl and Methods of Use
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US118780192024
Uses of Pyrimidopyrimidinones as SIK Inhibitors
Dana-farber Cancer Institute, Inc.
0 cites
US118588972024
Substituted 6,11-dihydro-5h-benzo[b]carbazoles as Inhibitors of ALK and SRPK
Dana-farber Cancer Institute, Inc.
0 cites
US118263652023
Type II Raf Kinase Inhibitors
Dana-farber Cancer Institute, Inc.
0 cites
US118276362023
Degradation of Cyclin-dependent Kinase 8 (CDK8) by Conjugation of CDK8 Inhibitors with E3 Ligase Ligand and Methods of Use
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US118143792023
Cyano Quinoline Amide Compounds as HER2 Inhibitors and Methods of Use
Dana-farber Cancer Institute, Inc.
0 cites
US118076062023
Sulfonamide Derivatives for Protein Degradation
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US117308182023
Degradation of Bruton's Tyrosine Kinase (BTK) by Conjugation of BTK Inhibitors with E3 Ligase Ligand and Methods of Use
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US117250112023
Bicyclic Urea Kinase Inhibitors and Uses Thereof
THE BROAD INSTITUTE, Inc.
0 cites
US117124582023
Degradation of Bruton's Tyrosine Kinase (BTK) by Conjugation of BTK Inhibitors with E3 Ligase Ligand and Methods of Use
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites
US116738822023
Pyrimidines as EGFR Inhibitors and Methods of Treating Disorders
Dana-farber Cancer Institute, Inc.
0 cites
US115847462023
Inhibitors of EGFR and Methods of Use Thereof
Dana-farber Cancer Institute, Inc.
0 cites
US115422512023
IRAK Degraders and Uses Thereof
DANA-FARBER CANCER INSTITUTE, Inc.
0 cites